Your Daily Pharmaceuticals Briefing

GSK and AbbVie Report Positive Cancer Drug Data Amidst New US Tariffs on Branded Pharma Imports

• GSK announced promising early-stage trial results for Mocertatug Rezetecan (Mo-Rez), an antibody-drug conjugate (ADC) for gynecological cancers, on April 12, 2026. The treatment demonstrated tumor shrinkage or elimination in 62% of ovarian cancer patients and 67% of endometrial cancer patients where chemotherapy had previously failed, leading the company to plan for late-stage trials.

  The Guardian

• AbbVie presented late-breaking Phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE®) at the Society of Gynecologic Oncology (SGO) Annual Meeting on April 12, 2026, revealing an objective response rate of 62.7% in patients with folate receptor alpha (FRα)-expressing, platinum-sensitive ovarian cancer. The findings highlight the drug's potential across the ovarian cancer treatment continuum, with a median duration of response of 11.2 months across the overall patient population.

  PrnewswireAbbvie

• The Trump administration announced a new 100% tariff on patented branded pharmaceutical products and their ingredients entering the U.S., effective with a phased rollout starting July 31, 2026, for large companies and September 29, 2026, for others. This policy, stemming from a Section 232 investigation into national security impacts of pharmaceutical imports, notably exempts generic pharmaceuticals and biosimilars, and a separate UK-US deal ensures British drug exports are also exempt, while EU and Ireland's pharmaceutical exports continue to face a 15% tariff.

  RsmusIrishexaminer